Avalo Therapeutics, Inc.
10
0
0
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
20.0%
2 terminated/withdrawn out of 10 trials
80.0%
-6.5% vs industry average
0%
0 trials in Phase 3/4
25%
2 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa
Role: lead
A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.
Role: lead
Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma
Role: lead
Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis
Role: lead
A Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults With Complex Lymphatic Malformations
Role: lead
A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment
Role: lead
A Study of Intermittent Doses of CERC-301 in MDD
Role: lead
An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory Cough
Role: lead
Antitussive Effects of FP01 Lozenges in Subjects With Cough Due to Upper Respiratory Tract Infection
Role: lead
A Single Dose Study to Determine the Safety and Pharmacokinetics of FP01 Lozenges in Healthy Volunteers
Role: lead
All 10 trials loaded